No Data
Japanese stock buybacks this week (12/23~12/27)
――――12/23――――$NHK Spring(5991.JP)$ will buy back up to 13 million shares, 6.05% of its outstanding shares (excluding its own shares), for an amount of JPY¥ 26 billion.――――12/24――――$Yamaha(7951.JP)$
December 27 [Today's Investment Strategy]
[Selected Stocks by Fisco] 【Material Stocks】 Kaken Pharmaceutical <4521> 4174 yen (12/26) Main products include the nail fungus treatment 'Klenafin' and the joint function improvement drug 'Alts'. The company announced the signing of a contract granting Johnson & Johnson exclusive rights for the development, manufacturing, and commercialization globally of the 'STAT6 Program', which is being developed as a next-generation oral treatment for type 2 inflammatory diseases (such as atopic dermatitis and asthma).
Focus on DeNA and Kaken Pharmaceutical, while Oisix and Sankyo Tateyama may be sluggish.
In the US stock market on the 26th, the Dow Jones Industrial Average rose by $28.77 to 43,325.80, the Nasdaq Composite Index fell by 10.77 points to 20,020.36, and the Chicago Nikkei 225 Futures were up by 210 yen compared to Osaka daytime at 39,700 yen. The exchange rate was 1 dollar = 158.00-10 yen. In today's Tokyo market, Kusuri no Aoki <3549> saw an increase in operating profit of 85.5%, expanding from 10.2% growth in the first quarter, and the performance of its gaming business for the fiscal year ending in March 2025 is expected to see an increase in both revenue and profit compared to the previous period.
Nifco and others announced their Share Buyback on December 26.
The stocks for which a stock buyback framework was announced on Thursday, December 26 are as follows: <7988> Nifco 0.58 million shares (0.6%) 2 billion yen (from 25/1/6 to 25/2/26), <1941> Chudenko 0.5 million shares (0.9%) 1.6 billion 50 million yen (on 24/12/27), <4109> Stellar Chemifa 0.24 million shares (2.0%) 1.2 billion yen (from 25/1/6 to 25/3/24), <7946> Koyo Co. 0.2 million shares (29.3%) 0.2 billion 60 million yen (from 25/3/5 to 25/3).
Chudenko: Confirmation letter
Chudenko: Semi-Annual Report - 109th Term (2024/04/01 - 2025/03/31)
No Data